Literature DB >> 3118820

Prospective study of serum staphylococcal antibodies in cystic fibrosis.

A E Hollsing1, M Granström, B Strandvik.   

Abstract

Serum IgG antibodies to teichoic acid and alpha toxin from Staphylococcus aureus were measured in 62 patients with cystic fibrosis by enzyme linked immunosorbent assays. The patients were followed up for 12-24 months in a prospective study. Raised titres were found exclusively in patients chronically colonised with S aureus. Patients colonised with both S aureus and Pseudomonas aeruginosa had significantly higher titres against teichoic acid than those carrying S aureus alone. Titres were significantly higher when there were clinical signs of low grade infection in the patients chronically colonised with S aureus alone, and in those with both S aureus and P aeruginosa. Significant reduction in titres occurred after antimicrobial treatment given either orally or intravenously in patients with normal erythrocyte sedimentation rates and white cell counts. Measurement of staphylococcal antibody titres may be valuable in monitoring pulmonary infection and antimicrobial treatment in patients with cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3118820      PMCID: PMC1778603          DOI: 10.1136/adc.62.9.905

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  18 in total

Review 1.  Cystic fibrosis--a challenging long-term chronic disease.

Authors:  L W Matthews; D Drotar
Journal:  Pediatr Clin North Am       Date:  1984-02       Impact factor: 3.278

2.  Prospective study of fatty acid supplementation over 3 years in patients with cystic fibrosis.

Authors:  E Kusoffsky; B Strandvik; S Troell
Journal:  J Pediatr Gastroenterol Nutr       Date:  1983       Impact factor: 2.839

Review 3.  The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis.

Authors:  M I Marks
Journal:  J Pediatr       Date:  1981-02       Impact factor: 4.406

4.  Pseudomonas colonization in cystic fibrosis. A study of 160 patients.

Authors:  L L Kulczycki; T M Murphy; J A Bellanti
Journal:  JAMA       Date:  1978-07-07       Impact factor: 56.272

5.  Serological diagnosis of deep Staphylococcus aureus infections by enzyme-linked immunosorbent assay (ELISA) for staphylococcal hemolysins and teichoic acid.

Authors:  M Granström; I Julander; R Möllby
Journal:  Scand J Infect Dis Suppl       Date:  1983

6.  Enzyme-linked immunosorbent assay for antibodies against teichoic acid in patients with staphylococcal infections.

Authors:  M Granström; I G Julander; S A Hedström; R Möllby
Journal:  J Clin Microbiol       Date:  1983-04       Impact factor: 5.948

7.  The role of antibodies against alpha-toxin and teichoic acid in the diagnosis of staphylococcal infections.

Authors:  I G Julander; M Granström; S A Hedström; R Möllby
Journal:  Infection       Date:  1983 Mar-Apr       Impact factor: 3.553

8.  Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis.

Authors:  B Strandvik; A S Malmborg; H Alfredson; A Ericsson
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

9.  Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis.

Authors:  M Szaff; N Høiby
Journal:  Acta Paediatr Scand       Date:  1982-09
View more
  8 in total

Review 1.  Cystic fibrosis. Infection and immunity to Staphylococcus aureus and Haemophilus influenzae.

Authors:  D P Greenberg; H R Stutman
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 2.  Clinical significance of Staphylococcus aureus in cystic fibrosis.

Authors:  M I Marks
Journal:  Infection       Date:  1990 Jan-Feb       Impact factor: 3.553

3.  Levels of antibody against 11 Staphylococcus aureus antigens in a healthy population.

Authors:  Patricia Colque-Navarro; Gunnar Jacobsson; Rune Andersson; Jan-Ingmar Flock; Roland Möllby
Journal:  Clin Vaccine Immunol       Date:  2010-05-05

4.  Antistaphylococcal antibodies in cystic fibrosis.

Authors:  B Strandvik; A Hollsing; R Möllby; M Granström
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

5.  Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis.

Authors:  A Albus; J M Fournier; C Wolz; A Boutonnier; M Ranke; N Høiby; H Hochkeppel; G Döring
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

6.  Host response to Staphylococcus aureus cytotoxins in children with cystic fibrosis.

Authors:  Ashley D Chadha; Isaac P Thomsen; Natalia Jimenez-Truque; Nicole R Soper; Lauren S Jones; Andrew G Sokolow; Victor J Torres; C Buddy Creech
Journal:  J Cyst Fibros       Date:  2016-01-25       Impact factor: 5.482

7.  Bacterial colonisation with Xanthomonas maltophilia--a retrospective study in a cystic fibrosis patient population.

Authors:  F Karpati; A S Malmborg; H Alfredsson; L Hjelte; B Strandvik
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

8.  High Prevalence of Staphylococcus aureus Enterotoxin Gene Cluster Superantigens in Cystic Fibrosis Clinical Isolates.

Authors:  Anthony J Fischer; Samuel H Kilgore; Sachinkumar B Singh; Patrick D Allen; Alexis R Hansen; Dominique H Limoli; Patrick M Schlievert
Journal:  Genes (Basel)       Date:  2019-12-12       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.